Skip to content

Sensory Symptoms in Active Vitiligo

Sensory Symptoms as an Early Manifestation of Active Vitiligo: a Case-control Clinical and Molecular Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05390164
Enrollment
90
Registered
2022-05-25
Start date
2022-05-25
Completion date
2022-08-15
Last updated
2022-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Totest Sensory Symptoms in Active Vitiligo

Brief summary

This work aims to assess sensory symptoms in early active vitiligo patients (segmental, non-segmental, or mixed) and to measure 3 neuropeptides expression in their lesional skin \[neuropeptide Y(NPY), calcitonin gene-related peptide (CGRP), and nerve growth factors (NGF)\] to correlate neuropeptide levels, sensory symptoms, and functions, with criteria of disease activity and perceived stress scale.

Detailed description

Study Design: Case-control study Population: 45 patients with active vitiligo and 45 patients with stable vitiligo Inclusion criteria: Age: 18 years old and older Sex: both sexes Exclusion criteria: Other hypopigmented diseases such as pityriasis alba, tinea versicolor, lichen sclerosis, post-inflammatory hyperpigmentation, and leprosy as excluded by lack of accentuation by wood's light examination. - Cases who received treatment (systemic or topical) in the last 3 months before sampling. - Neurological or other diseases that cause itching. - Medical history of DM, HTN, or other systemic diseases, history of associated autoimmune diseases. Assessment will be carried as follows: • History of itching or other abnormal neurological sensations as paresthesia and numbness. Aggravating factors (e.g. dryness, hot environment, sun exposure, ..etc), alleviating factors of itching Type of vitiligo (segmental, unilateral, vulgaris). • Assessment of activity by assessing: koebner's phenomenon, confetti depigmentation, trihypochrome areas, poorly defined borders, inflammatory signs (e.g eye inflammation and hearing loss), and leukotrichia. • Assessment of sensory symptoms and signs (fine touch, crude touch, pain, and sweating by starch iodine test) in active vitiliginous patches. • Clinical assessment: the vitiligo area score index (VASI), vitiligo extent scores (VES), vitiligo disease activity score (VIDA) (Feily, 2014) will be assessed in every participant and demographic data

Interventions

DIAGNOSTIC_TESTskin biopsy

skin biopsy to be analyzed by ELISA

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Active and stable vitiligo

Exclusion criteria

* Diabetic or other associated disease

Design outcomes

Primary

MeasureTime frameDescription
Neuropeptide3 monthslaboratory test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026